Zoetis Inc. (NYSE:ZTS) Receives $160.18 Average Target Price from Analysts

Zoetis Inc. (NYSE:ZTS) has earned a consensus recommendation of “Hold” from the fourteen brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $160.1818.

A number of equities analysts have issued reports on ZTS shares. UBS Group decreased their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Stifel Nicolaus lowered their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. Bank of America cut shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price target on the stock. in a research report on Monday, December 15th. Weiss Ratings restated a “sell (d+)” rating on shares of Zoetis in a research report on Monday, December 29th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th.

Hedge Funds Weigh In On Zoetis

A number of hedge funds have recently modified their holdings of the stock. Norges Bank acquired a new stake in shares of Zoetis during the second quarter worth $809,491,000. Diamond Hill Capital Management Inc. acquired a new stake in Zoetis during the 3rd quarter worth about $394,010,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Zoetis by 113.0% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after buying an additional 1,995,491 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in Zoetis by 83.4% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company’s stock valued at $394,746,000 after buying an additional 1,227,085 shares in the last quarter. Finally, Corient Private Wealth LLC boosted its holdings in shares of Zoetis by 85.9% in the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after buying an additional 1,191,840 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS opened at $125.77 on Tuesday. The firm has a market capitalization of $55.43 billion, a PE ratio of 21.17, a P/E/G ratio of 2.57 and a beta of 0.97. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The firm has a 50-day moving average price of $125.02 and a 200 day moving average price of $141.61. Zoetis has a 52-week low of $115.25 and a 52-week high of $177.40.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts anticipate that Zoetis will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.7%. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.